Race Plays a Key Role in Prostate Cancer Survival Rates
Prostate Cancer and Race
Japanese American men respond better to hormonal treatment for prostate cancer and have a much higher survival rate than white American men, according to research published in the latest issue of the urology journal BJU International.
A team of researchers from the US and Japan compared 59 white males and 105 Japanese American males who had receive hormone treatment for prostate cancer at The Queen's Medical Centre in Honolulu, Hawaii.
They discovered that, although there was little difference between the patients' backgrounds and ages, five years after the treatment started the overall survival rate for the Japanese American patients was 66 percent, compared with 42 percent for the white men in the sample.
The result between the two ethnic groups did not appear to be affected by whether the men's cancer was confined to the prostate or had spread to other parts of the body.
However the survival rates tended to even out in the most advanced cancers, when the levels of the Prostate-Specific Antigen (PSA) protein produced by the prostate exceeded 100. About a quarter of the study sample had PSA readings in this range.
"Japanese men have one of the lowest rates of prostate cancer worldwide, but levels tend to be higher among Japanese American men, compared with those who actually live in Japan," says lead author Dr. Takashi Fukagai, a urologist at the Showa University School of Medicine in Tokyo.
"One theory is that Japanese Americans retain some native Japanese genetic and, or, lifestyle characteristics that lead to them developing prostate cancer less frequently than white American men.
"We also have a ongoing study of other ethnic groups, which has shown that Chinese men living in Hawaii have a similar prognosis to Japanese American men. We have also discovered that Filipino men have a worse prognosis than those two ethnic groups, but still enjoy a higher survival rate than white men.
The men who took part in the study had an average age of 76 and had all received hormonal treatment from the same team or urologists. Hormone therapy blocks the action of the male sex hormones that help the cancer cells grow, either through administering testosterone lowering drugs or by removing the testosterone-producing testicles.
None of the study subjects had received definitive surgical or radiation therapy.
Five factors were examined in detail